Shelley Izquierdo is Senior Director of Antibody Discovery at OmniAb. With over 15 years of experience in developing antibody discovery technology and leading project management at Trellis Biosciences and Crystal Bioscience. Dr. Izquierdo joined the OmniAb team in 2017 following Ligand Pharmaceuticals’ acquisition of Crystal Bioscience, where she developed and optimized the best-in-class GEM assay for multiplexed analysis of single B cells. The GEM assay has become a cornerstone for recovering antibodies from immunized chickens, including the OmniChicken®, which is the world’s first transgenic chicken producing human sequence antibodies. In addition to continuing to implement technological process improvements, she oversees a wide variety of OmniChicken partner projects, where she primarily focuses on discovery programs to generate antibodies to high homology targets and when partner requirements call for broad epitope coverage and high species cross-reactivity. Dr. Izquierdo received her PhD. in Molecular and Cell Biology from the University of California Berkeley.
